Capital Advisors Ltd’s Akero Therapeutics AKRO Stock Holding History

Capital Advisors Ltd’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6	Closed	–	–	1177
2022 Q4	$0	Buy	+6	New	+$257	﹤0.01%	1182

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Advisors Ltd's AKRO Position: Q1 2023 in Review

Capital Advisors Ltd sold out of Akero Therapeutics (AKRO) in Q1 2023, closing a stake of 6 shares.

Capital Advisors Ltd first reported a position in AKRO in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 156 funds tracked by Wall St. Rank hold AKRO as of Q1 2023.

Capital Advisors Ltd reported no remaining Akero Therapeutics position as of Q1 2023 after selling out during the quarter.
Capital Advisors Ltd sold 6 Akero Therapeutics shares in Q1 2023.
Capital Advisors Ltd first reported a position in Akero Therapeutics in Q4 2022 and held it in 1 quarter.
Capital Advisors Ltd's Akero Therapeutics position peaked at $0 in Q4 2022.
156 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2023.

Based on Capital Advisors Ltd's 13F filing for Q1 2023, filed 3 May 2023.